Significantly Decreased LMK‑CT Score vs Placebo at Week 24 (Key Secondary Endpoint) With Sustained Improvement Through Week 52 (Other Secondary Endpoint) in SINUS‑521,2,a

aAnalysis of change at Week 52 was not multiplicity controlled; result is descriptive.

 

SEE THE SCANS FROM A REAL DUPIXENT PATIENT
Click and drag
to see results

CT scan of patient from clinical trial. Individual results may vary.

SINUS-52
CHANGE IN LMK-CT SCORES1,2,a
 DUPIXENT® (dupilumab) clinical trials showed 29% improvement in LMK-CT scores at week 24 and a 37% improvement at week 52

aAnalysis of change at Week 52 was not multiplicity controlled; result is descriptive.

DUPIXENT demonstrated statistically significant reductions in opacification across all individual sinuses AT WEEK 241,2

Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.